Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517802 · ClinicalTrials.gov registry record · Phase 3
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT01517802 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 32 participants.
The verdict
NCT01517802, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
Interventions
- DRUG Prednisone
- DRUG Abiraterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517802
The ClinicalTrials.gov registry entry for NCT01517802 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT01517802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01517802 about?
NCT01517802 is a clinical study titled "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate". The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
What is the current status of trial NCT01517802?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2012-03-28. Estimated completion is 2021-04-22.
What interventions are being tested in trial NCT01517802?
The interventions under investigation include: Prednisone (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT01517802?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.